Overview

Aplenzin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD). Individuals may be prescribed Aplenzin for short-term or long-term treatment depending on their specific symptoms and treatment response. It is not approved for use in children and carries a boxed warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults. Aplenzin is also known by its generic name, bupropion hydrobromide.

Bupropion hydrobromide is an aminoketone antidepressant. It works by affecting the levels of norepinephrine and dopamine, two neurotransmitters involved in regulating mood and emotional balance.

How do I take it?

Prescribing information states that bupropion hydrobromide is taken by mouth as an extended-release tablet once daily. After four days, the starting dose may be increased. The medication should be taken exactly as prescribed by a healthcare provider.

Side effects

Common side effects of Aplenzin include xerostomia (dry mouth), nausea, insomnia, vertigo (dizziness), pharyngitis (sore throat), abdominal pain, agitation, anxiety, tremor, palpitations (rapid heartbeat), hyperhidrosis (sweating), tinnitus (ringing in the ears), myalgia (muscle pain), anorexia (loss of appetite), increased urinary frequency, and rash.

Rare but serious side effects may include seizures, hypertension (high blood pressure), manic or hypomanic episodes, hallucinations, delusions, psychosis, suicidal ideation (thoughts of suicide), and angle-closure glaucoma (a type of eye emergency due to increased pressure). Neuropsychiatric reactions, including paranoia and homicidal ideation, have also been reported in people using Aplenzin for smoking cessation.

For more information about this treatment, visit:

Label: Aplenzin — Bupropion Hydrobromide Tablet, Extended Release — DailyMed